No Data
No Data
Fangda Holdings (01521.HK)'s revenue for the first quarter was about 63.9 million US dollars, up 8.3% year-on-year
Gelonghui, April 25 | Fangda Holdings (01521.HK) announced that for the three months ended March 31, 2024, the Group recorded a net loss of about 1.0 million US dollars, while the net loss was about 0.9 million US dollars for the same period in 2023; revenue was about 63.9 million US dollars, an increase of 8.3% over the same period of about 59.0 million US dollars in the same period in 2023. After deducting share-based compensation expenses, amortization of intangible assets from mergers and acquisitions, and merger-related expenses, the Group's adjusted net profit was approximately US$2.2 million, an increase of 15.8% over the same period in 2023 of approximately US$1.9 million.
方達控股:2023年度報告
Haitong International: Maintaining Fangda Holdings (01521)'s “superior to market” rating target price reduction of 44% to HK$1.89
The Zhitong Finance App learned that Haitong International released a research report stating that maintaining the “superior to market” rating of Fangda Holdings (01521) was affected by the decline in global biomedical investment and financing growth, adjusted the company's 2024-2026 revenue to US$3,360, and 422 million, respectively; the adjusted net profit was US$0.34, 0.43, and US$52 million, with year-on-year growth rates of 40%, 28%, and 20%, respectively, cutting the target price from HK$3.4 to HK$1.89. In North America, the company acquired Nuro in Toronto, Canada
Fangda Holdings (01521.HK): Short-term fluctuations in performance are optimistic about the company's long-term steady development
The company announced 2023 results: In 2023, operating income was $259.9 million (+3.8%), gross margin was 30.2% (-5.4pp), and net profit was $10.7 million (-58.7%)
Fangda Holdings (01521.HK) cancelled 63.1 million shares on April 15
Gelonghui, April 15, 丨 Fangda Holdings (01521.HK) announced that on April 15, 2024, the company cancelled 63.1 million repurchased shares.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
No Data